Evidence map›Paper›PMID 28713557›Full record

ReviewF1000Research2017

Yin and yang of interleukin-17 in host immunity to infection.

Shibali Das, Shabaana Khader

Open access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Expression of IL-1β in transgenicFrontiers in immunology · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Research advances on the regulation of interleukin-17 signal transduction and the implication of interleukin-17 in sepsis].Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns · 2021
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Interleukin-17 mediated immunity during infections with Trypanosoma cruzi and other protozoans.Biochimica et biophysica acta. Molecular basis of disease · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Shibali DasDepartment of Molecular Microbiology, Washington University in St. Louis, St Louis, MO, USA.
Shabaana KhaderDepartment of Molecular Microbiology, Washington University in St. Louis, St Louis, MO, USA.ORCID 0000-0002-9545-4982
Washington University in St. Louis · US

Funding

ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1M
ROLE OF IL-17 IN PROTECTIVE VACCINE-INDUCED IMMUNE RESPONSES AGAINST TUBERCULOSISR01HL105427 · NHLBI · WASHINGTON UNIVERSITY · PI KHADER, SHABAANA A. · 2011 to 2025
$5.9M
COMMON IMMUNE CORRELATES OF RISK OF TB DISEASE IN ANIMAL MODELS AND HUMANSR01AI123780 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2016 to 2019
$2.9M
NHLBI NIH HHS R01 HL105427NIAID NIH HHS R01 AI111914NIAID NIH HHS R01 AI123780
6 · The paper itself

Abstract

The interleukin-17 (IL-17) family cytokines, such as IL-17A and IL-17F, play important protective roles in host immune response to a variety of infections such as bacterial, fungal, parasitic, and viral. The IL-17R signaling and downstream pathways mediate induction of proinflammatory molecules which participate in control of these pathogens. However, the production of IL-17 can also mediate pathology and inflammation associated with infections. In this review, we will discuss the yin-and-yang roles of IL-17 in host immunity to pathogens.

Indexed as

host immune responseIL-17pathogens

Identifiers

PMID28713557
PMCPMC5490359
OpenAlexW2619607443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.